MedTrace Logo

On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection

NCT02376478 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 222

Last updated 2015-03-03

No results posted yet for this study

Summary

In this prospective, open, controlled, cross-sectional observational study patients with psoriasis or IBD, who received either anti-TNF-alpha inhibitors or alternates (purine-, folic acid analogues, phototherapy, fumaric ester, mesalazine) for their underlying disease were included.

Anogenital HPV-induced lesions, mucosal HPV DNA and serological status of mucosal low-risk (HPV6) and high-risk HPV (HPV16, HPV18) were determined.

Conditions

Interventions

DRUG

TNF-alpha inhibitors

therapy for at least 6 months

DRUG

Alternative/no medication

therapy for at least 6 months or no therapy

OTHER

Alternative/no medication

phototherapy for at least 6 months

DRUG

Purine/folic acid analogues

therapy for at least 6 months

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Reinhard Kirnbauer, MD · Medical University of Vienna

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2011-01-31
Completion
2011-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02376478 on ClinicalTrials.gov